Skip to main content

Advertisement

SpringerLink
Log in

Antipsychotic treatment for late-life schizophrenia

  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

The clinical characteristics of schizophrenia in older persons vary to some extent, depending on whether the onset of illness was earlier or later in life. Regardless of age of onset, antipsychotic medications are the mainstay of treatment. Age-related physiologic changes make older persons more sensitive to the therapeutic and toxic effects of antipsychotics. There is a paucity of controlled studies on the efficacy of antipsychotic medications in older persons with schizophrenia. Existing data suggest that atypical antipsychotics are at least as efficacious as and better tolerated than the conventional agents. In late-life schizophrenia, important adverse effects of antipsychotics include sedating, anticholinergic and cardiovascular effects, extrapyramidal symptoms, and tardive dyskinesia. Certain atypical antipsychotics are associated with a risk of metabolic changes as well as agranulocytosis. Clinical recommendations include a thorough diagnostic evaluation followed by treatment with low doses of atypical antipsychotics. Medication alone is likely to be less effective than when it is combined with an appropriate psychosocial intervention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Jeste DV, Alexopoulos GS, Bartels SJ, et al.: Consensus statement on the upcoming crisis in geriatric mental health: Research agenda for the next two decades. Arch Gen Psychiatry 1999, 56:848–853. This paper describes the current shortage of available psychiatric treatment for older adults. The authors propose a 15- to 25-year agenda for the research of late-life psychiatric disorders (including schizophrenia) aimed at keeping pace with the projested growth of the population of older adults.

    Article  PubMed  CAS  Google Scholar 

  2. Palmer BW, Heaton SC, Jeste DV: Older patients with schizophrenia: challenges in the coming decades. Psychiatr Serv 1999, 50:1178–1183.

    PubMed  CAS  Google Scholar 

  3. Palmer BW, McClure F, Jeste DV: Schizophrenia in late-life: findings challenge traditional concepts. Harvard Rev Psychiatry 2001, 9:51–58.

    Article  CAS  Google Scholar 

  4. Jeste DV, Lacro JP, Gilbert PL, et al.: Treatment of late-life schizophrenia with neuroleptics. Schizophr Bull 1993, 19:817–830.

    PubMed  CAS  Google Scholar 

  5. Roth M: The natural history of mental disorder in old age. J Ment Sci 1955, 101:281–301.

    PubMed  CAS  Google Scholar 

  6. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, edn 3 [revised]. Washington, DC: American Psychiatric Press; 1987.

    Google Scholar 

  7. Harris MJ, Jeste DV: Late-onset schizophrenia: an overview. Schizophr Bull 1988, 14:39–55.

    PubMed  CAS  Google Scholar 

  8. Howard R, Rabins PV, Seeman MV, et al.: Late-onset schizophrenia and very-late-onset schizophrenia-like psychois: an international consensus. Am J Psychiatry 2000, 157:172–178. This paper clarifies the diagnosis, nomenclature, and treatment guidelines for schizophrenia presenting in middle (age older than 40) and old (age older than 60) age. Findings are based on a systematic review of the literature and 2 days of discussion by members of the International Late-onset Schizophrenia Group.

    Article  PubMed  CAS  Google Scholar 

  9. Jeste DV, Symonds LL, Harris MJ, et al.: Non-dementia non-praecox dementia praecox? Late-onset schizophrenia. Am J Geriatr Psychiatry 1997, 5:302–317.

    PubMed  CAS  Google Scholar 

  10. Jeste DV, Harris MJ, Pearlson GD, et al.: Late-onset schizophrenia: studying clinical validity. Psychiatr Clin North Am 1988, 11:1–14.

    PubMed  CAS  Google Scholar 

  11. Heaton R, Paulsen J, McAdams LA, et al.: Neuropsychological deficits in schizophrenia: Relationship to age, chronicity and dementia. Arch Gen Psychiatry 1994, 51:469–476.

    PubMed  CAS  Google Scholar 

  12. Byrd DA, Paulsen RK, Heaton RK, et al.: A qualitative analysis of intrusion erros in schizophrenia. J Int Neuropsychol Soc 1996, 2:55.

    Google Scholar 

  13. Paulsen JS, Romero R, Chan A, et al.: Impairment of the semantic network in schizophrenia. Psychiatry Res 1996, 63:109–121.

    Article  PubMed  CAS  Google Scholar 

  14. Bleuler M: A 23-year longitudinal study of 208 schizophrenics and impressions in regard to the nature of schizophrenia. In The Transmission of Schizophrenia. Edited by Rosenthal D, Kety SS. New York: Pergamon Press; 1968:3–12.

    Google Scholar 

  15. Huber G, Gross G, Schuttler R, Linz M: Longitudinal studies of schizophrenia patients. Schizophr Bull 1980, 6:592–605.

    PubMed  CAS  Google Scholar 

  16. Harding CM, Brooks GW, Ashikaga T, et al.: The Vermont longitudinal study: II. Long-term outcome of subjects who once met the criteria for DSM-III schizophrenia. Am J Psychiatry 1987, 144:727–735.

    PubMed  CAS  Google Scholar 

  17. Carpenter WT, Kirkpatrick B: The heterogeneity of the long-term course of schizophrenia. Schizophr Bull 1988, 14:645–652.

    PubMed  Google Scholar 

  18. McGlashan TH: A selective review of recent North American long-term followup studies of schizophrenia. Schizophr Bull 1988, 14:515–542.

    PubMed  CAS  Google Scholar 

  19. Belitsky R, McGlashan TH: The manifestations of schizophrenia in late life: a dearth of data. Schizophr Bull 1993, 19:683–685.

    PubMed  CAS  Google Scholar 

  20. Winokur G, Pfohl B, Tsuang M: A 40-year follow-up of hebephrenic-catatonic schizophrenia. In Schizophrenia and Aging. Edited by Miller NE, Cohen GD. New York: Guilford; 1987:52–60.

    Google Scholar 

  21. Ciompi L: Catamnestic long-term study on the course of life and aging of schizophrenics. Schizophr Bull 1980, 6:606–618.

    PubMed  CAS  Google Scholar 

  22. Heaton RK, Gladsjo JA, Palmer BW, et al.: Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry 2001, 58:24–32. This paper compares the neuropsychologic performances of 142 patients with schizophrenia and 206 normal comparison subjects over a mean 3-year period. Although patients with schizophrenia show significantly more impairment than normal comparison subjects, the impairment appears to remain stable over time in community-dwelling outpatients.

    Article  PubMed  CAS  Google Scholar 

  23. Evans JD, Negron AE, Palmer BW, et al.: Cognitive deficits and psychopathology in hospitalized versus community-dwelling elderly schizophrenia patients. J Geriatr Psychiatry Neurol 1999, 12:11–15.

    Article  PubMed  CAS  Google Scholar 

  24. Sweet RA, Pollock BG: New atypical antipsychotics: experience and utility in the elderly. Drugs Aging 1998, 12:115–127.

    Article  PubMed  CAS  Google Scholar 

  25. Rowell FJ, Hui SM, Fairbairn AF, Eccleston D: The effect of age and thioridazine on the in vitro binding of fluphenazine to normal human serum. Br J Clin Pharmacol 1980, 9:432–433.

    PubMed  CAS  Google Scholar 

  26. Caligiuri MP, Jeste DV, Lacro JP: Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging 2000, 17:363–384.

    Article  PubMed  CAS  Google Scholar 

  27. McClure FS, Jeste DV: Treatment of late-onset schizophrenia and related disorders. In Leeds Castle Symposium. Edited by Howard R. New York: Leeds Castle; 1998.

    Google Scholar 

  28. Post F: Persistent Persecutory States of the Elderly. London: Pergamon Press; 1966.

    Google Scholar 

  29. Rabins P, Pauker S, Thomas J: Can schizophrenia begin after age 44? Compr Psychiatry 1984, 25:290–293.

    Article  PubMed  CAS  Google Scholar 

  30. Craig TJ, Bregman Z: Late onset schizophrenia-like illness. J Am Geriatr Soc 1988, 36:104–107.

    PubMed  CAS  Google Scholar 

  31. Pearlson GD, Kreger L, Rabins RV, et al.: A chart review study of late-onset and early-onset schizophrenia. Am J Psychiatry 1989, 146:1568–1574.

    PubMed  CAS  Google Scholar 

  32. Howard R, Levy R: Which factors affect treatment response in late paraphrenia? Int J Geriatr Psychiatry 1992, 7:667–672.

    Article  Google Scholar 

  33. Honigfeld G, Rosebaum MP, Blumenthal IJ, et al.: Behavioral improvement in the older schizophrenic patient: drug and social therapies. J Am Geriatr Soc 1965, 13:57–71.

    PubMed  CAS  Google Scholar 

  34. Tsuang MM, Lu LM, Stotsky BA, Cole JO: Haloperidol versus thioridazine for hospitalized psychogeriatric patients: double-blind study. J Am Geriatr Soc 1971, 19:593–600.

    PubMed  CAS  Google Scholar 

  35. Branchey MH, Lee JH, Ramesh A: High-and low-potency neuroleptics in elderly psychiatric patients. JAMA 1978, 239:1860–1862.

    Article  PubMed  CAS  Google Scholar 

  36. Kane JM, Honigfeld G, Singer J, et al.: Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988, 45:789–796.

    PubMed  CAS  Google Scholar 

  37. Casey DE: Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia. J Clinl Psychiatry 1998, 59(suppl):31–37.

    CAS  Google Scholar 

  38. Alvir JMaJ, Lieberman JA, Safferman AZ, et al.: Clozapineinduced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993, 329:162–167.

    Article  PubMed  CAS  Google Scholar 

  39. Howanitz E, Pardo M, Smelson DA: The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. J Clin Psychiatry 1999, 60:41–44.

    Article  PubMed  CAS  Google Scholar 

  40. Sajatovic M, Ramirez LF, Garver D, et al.: Clozapine therapy for older veterans. Psychiatr Serv 1998, 49:340–344.

    PubMed  CAS  Google Scholar 

  41. Madhusoodanan S, Brecher M, Brenner R, et al.: Risperidone in the treatment of elderly patients with psychotic disorders. Am J Geriatr Psychiatry 1999, 7:132–138.

    PubMed  CAS  Google Scholar 

  42. Davidson M, Harvey PD, Vervarcke J, et al.: A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis-on behalf of the Risperidone Working Group. Int J Geriatr Psychiatry 2000, 15:506–514.

    Article  PubMed  CAS  Google Scholar 

  43. Jeste DV, Eastham JH, Lacro JP, et al.: Management of late-life psychosis. J Clin Psychiatry 1996, 57(suppl):39–45.

    PubMed  Google Scholar 

  44. Jeste DV, Madhusoodanan S, Barak Y, Martinez RA: Comparison of risperidone and olanzapine in elderly patients with schizophrenia and schizoaffective disorder: a randomized double-blind study [abstract]. Paper presented at the 15th Annual Meeting of American Association of Geriatric Psychiatry; Orlando, FL. February 24 to 27, 2002;

  45. Katz IR, Jeste DV, Mintzer JE, et al.: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trail. J Clin Psychiatry 1999, 60:107–115.

    Article  PubMed  CAS  Google Scholar 

  46. Gilmore J, McGuire G, Kennedy JS: Acute double-blind comparison of olanzapine and haloperidol in schizophrenia patients age greater than 60. Paper presented at the 15th Annual Meeting of American Association of Geriatric Psychiatry; Orlando, FL. February 24 to 27, 2002;

  47. Street JS, Clark WS, Gannon KS, et al.: Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind randomized, placebo-controlled trial. Arch Gen Psychiatry 2000, 10:968–976.

    Article  Google Scholar 

  48. McManus DQ, Arvanitis LA, Kowalcyk BB: Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. J Clin Psychiatry 1999, 60:292–298.

    Article  PubMed  CAS  Google Scholar 

  49. Stimmel GL, Gutierrez MA, Lee V: Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. Clin Ther 2002, 24:21–37.

    Article  PubMed  CAS  Google Scholar 

  50. Saha AR, Petrie JL, Ali MW: Safety and efficacy profile of aripiprazole: a novel antipsychotic. Schizophr Res 1999, 36:295–296.

    Google Scholar 

  51. Campbell AJ: Drug treatment as a cause of falls in old age: a review of the offending agents. Drug Aging 1991, 1:289–302.

    CAS  Google Scholar 

  52. Maixner SM, Mellow AM, Tandon R: The efficacy, safety, and tolerability of antispychotics in the elderly. J Clin Psychiatry 1999, 60(suppl):29–41.

    PubMed  Google Scholar 

  53. Caligiuri MP, Lacro JP, Jeste DV: Incidence and predictors of drug-induced parkinsonism in older psychiatric patients treated with very low doses of neuroleptics. J Clin Psychopharmacol 1999, 19:322–328.

    Article  PubMed  CAS  Google Scholar 

  54. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, edn 4. Washington, DC: American Psychiatric Association; 2000.

    Google Scholar 

  55. Jeste DV, Caligiuri MP, Paulsen JS, et al.: Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 patients. Arch Gen Psychiatry 1995, 52:756–765.

    PubMed  CAS  Google Scholar 

  56. Woerner MG, Alvir JM, Saltz BL, et al.: Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 1998, 155:1521–1528.

    PubMed  CAS  Google Scholar 

  57. Jeste DV, Rockwell E, Harris MJ, et al.: Conventional vs. newer antipsychotics in elderly patients. Am J Geriatr Psychiatry 1999, 7:70–76.

    PubMed  CAS  Google Scholar 

  58. Saltz BL, Woerner MG, Kane JM, et al.: Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991, 266:2402–2406.

    Article  PubMed  CAS  Google Scholar 

  59. Kane JM, Woerner M, Lieberman J: Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988, 8:52S-56S.

    Article  PubMed  CAS  Google Scholar 

  60. Jeste DV, Lacro JP, Palmer BW, et al.: Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am J Psychiatry 1999, 156:309–311.

    PubMed  CAS  Google Scholar 

  61. Jeste DV, Lacro JP, Bailey A, et al.: Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999, 47:716–719.

    PubMed  CAS  Google Scholar 

  62. Jeste DV, Glazer WM, Morgenstern H: Low incidence of persistent tardive dyskinesia with quetiapine treatment of psychotic disorders in the elderly [abstract]. Am J Geriatr Psychiatry 2000, 8:25–26.

    Article  Google Scholar 

  63. Newcomer JW, Haupt Dw, Fucetola R: Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002, 59:337–345.

    Article  PubMed  CAS  Google Scholar 

  64. Sernyak MJ, Leslie DL, Alarcon RD: Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002, 159:561–566.

    Article  PubMed  Google Scholar 

  65. Jin H, Meyer JM, Jeste DV: The phenomenology of new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002, In press.

  66. Halbreich U, Palter S: Accelerated osteoporosis in psychiatric patients: Possible pathophysiological processes. Schizophr Bull 1996, 22:447–454.

    PubMed  CAS  Google Scholar 

  67. Webster P, Wijeratne C: Risperidone-induced neuroleptic malignant syndrome. Lancet 1994, 344:1228–1229.

    Article  PubMed  CAS  Google Scholar 

  68. Burkhard PR, Vingerhoets FJG, Alberque C, Landis T: Olanzapine-induced neuroleptic malignant syndrome. Arch Gen Psychiatry 1999, 56:101–102.

    Article  PubMed  CAS  Google Scholar 

  69. Whaley N, Diaz P, Howard J: Neuroleptic malignant syndrome associated with the use of quetiapine. Can J Hosp Pharmacy 1999, 52:112.

    Google Scholar 

  70. Morris SK, Jeste DV: Schizophrenia and other psychotic disorders. In Principles of Geriatric Medicine and Gerontology. Edited by Hazzard WR, Blass JP, Ettinger Jr. WH, Halter JB, Ouslander JG. New York: McGraw-Hill, Inc.; 1997.

    Google Scholar 

  71. Howard R: Study on Schizophrenia: drug treatment of schizophrenia and delusional disorder in late life. Int Psychogeriatr 1996, 8:597–608.

    Article  PubMed  CAS  Google Scholar 

  72. Granholm E, McQuaid JR, McClure FS, et al.: A randomized controlled pilot study of cognitive behavioral social skills training for older patients with schizophrenia. Schizophr Res 2001, 53:167–169.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of California, San Diego and the VA San Diego Healthcare System, 3350 La Jolla Village Drive, 92161, San Diego, CA, USA

    Dilip V. Jeste MD

Authors
  1. Jeremy A. Sable MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dilip V. Jeste MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sable, J.A., Jeste, D.V. Antipsychotic treatment for late-life schizophrenia. Curr Psychiatry Rep 4, 299–306 (2002). https://doi.org/10.1007/s11920-996-0050-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-996-0050-y

Keywords

Search

Navigation